Clinical trial
SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not…
NCT00096499 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00096499 |
|---|---|
| Title | SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel |
| Official title | A Phase II Study of SB-715992 (NSC-727990, IND-70273) in Taxane-Resistant Androgen-Independent Metastatic Prostate Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer |
| Intervention type | Drug, Other |
| Interventions | ispinesib, pharmacological study, laboratory biomarker analysis |
| Enrollment | 40 |
| Start date | Apr 1, 2005 |
| Primary completion | Jan 1, 2007 |
| First posted | Nov 10, 2004 |
| Last update posted | Jan 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: